Pharmanex Cholestin regulatory status decision expected by year-end, FDA says.
This article was originally published in The Tan Sheet
Executive Summary
FDA AIMING FOR CHOLESTIN REGULATORY STATUS DECISION BY YEAR-END, the agency says in a Nov. 14 letter to Pharmanex outside counsel Patton Boggs of Washington, D.C. "FDA believes that the quickest and most appropriate route under the agency's regulations to a final decision in this matter is for the commissioner to initiate an administrative proceeding...to decide the regulatory status of Cholestin," the letter states. "The agency will use its best efforts to conclude the proceeding and render a final decision on Cholestin by the end of the year."
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning